DeepMed Research

Salarius Pharmaceuticals, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study of SP-3164 in Relapsed or Refractory Non-Hodgkin's Lymphoma

Early Phase 1

Not yet recruiting

Conditions: Lymphoma, Non-Hodgkin's, Adult

Interventions: Drug: SP-3164

First Posted Date: 2023-08-07

Last Posted Date: 2023-11-22

Lead Sponsor: Salarius Pharmaceuticals, LLC

Target Recruit Count: 72

Registration Number: NCT05979857

A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)

Phase 1

Conditions: Ewing Sarcoma
Low Grade Fibromyxoid Sarcoma
Extraskeletal Myxoid Chondrosarcoma
Desmoplastic Small Round Cell Tumor
Clear Cell Sarcoma
Myxoid Liposarcoma
Angiomatoid Fibrous Histiocytoma
Sclerosing Epithelioid Fibrosarcoma
Myoepithelial Tumor

Interventions: Drug: Seclidemstat

First Posted Date: 2022-03-04

Last Posted Date: 2023-08-01

Lead Sponsor: Salarius Pharmaceuticals, LLC

Target Recruit Count: 10

Registration Number: NCT05266196

Locations: 🇺🇸
Sarcoma Oncology Center, Santa Monica, California, United States

Phase 1 Trial of the LSD1 Inhibitor SP-2577 (Seclidemstat) in Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Drug: SP-2577 Seclidemstat

First Posted Date: 2019-03-29

Last Posted Date: 2021-10-18

Lead Sponsor: Salarius Pharmaceuticals, LLC

Target Recruit Count: 23

Registration Number: NCT03895684

Locations: 🇺🇸
Sarcoma Oncology Research Center, Santa Monica, California, United States
🇺🇸
HonorHealth, Scottsdale, Arizona, United States

Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas

Phase 1

Active, not recruiting

Conditions: Ewing Sarcoma
Clear Cell Sarcoma
Myoepithelial Tumor
Desmoplastic Small Round Cell Tumor
Angiomatoid Fibrous Histiocytoma
Myxoid Liposarcoma
Sarcoma,Soft Tissue
Extraskeletal Myxoid Chondrosarcoma
Sclerosing Epithelioid Fibrosarcoma
Fibromyxoid Tumor

Interventions: Drug: Seclidemstat
Drug: Cyclophosphamide
Drug: Topotecan

First Posted Date: 2018-07-26

Last Posted Date: 2023-11-21

Lead Sponsor: Salarius Pharmaceuticals, LLC

Target Recruit Count: 50

Registration Number: NCT03600649

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Sarcoma Oncology Research Center, Santa Monica, California, United States

and more 12 locations

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy